The world becomes more interdependent every day. Nowhere is this more true than in the field of global health, where diseases spread at least as fast as the knowledge to contain them. The Foundation has made a contribution towards the University of Oxford's extensive global health programs for a variety of important purposes: to provide scholarships for students of Oxford's Global Health Sciences Master of Science (MS) program; to set up collaborations between researchers in Asia and at Oxford; and to fund a global health teaching program conducted by Oxford experts at Shantou University in Guangdong, China.

• The programs will be administered by a board of senior Oxford University health scientists led by Professor Jeremy Farrar, a world expert on infectious diseases.
  
  
• Oxford University's MS in Global Health Sciences is designed to equip leaders in global health science and practice with knowledge and skills, ranging from tropical and infectious medicine, epidemiology, and public health to development studies and health economics. The donation will fund four scholarships each year enabling exceptional students from Asia and Africa to gain skills and knowledge to combat diseases in their own countries.
  
• The donation will result in funds being readily available for research projects in global health, particularly new projects that have a significant impact on health issues relevant to Asia.
  
• A teaching program at Shantou University will facilitate eminent Oxford University researchers in global health contribute to an annual teaching course for undergraduates and postgraduates studying medicine, epidemiology, health sciences, and infectious diseases.

Oxford University's world-leading global health program targets killer diseases including AIDS, tuberculosis, malaria, emerging diseases such as dengue fever and avian flu, stroke, heart disease, and cancer. Long-term studies of patients in tropical countries are supported by basic science at Oxford and have led to many exciting developments, most notably the use of artemisinin combinations for the treatment of malaria (based on Chinese traditional medicine) and potential vaccines for tuberculosis, malaria, and AIDS, all of which are in clinical trials.